Invitae is interested in companies that can contribute positively to its revenues in the next two to three quarters, according to CEO Sean George.
The acquisitions will enable Invitae to add reproductive health genetic testing to its portfolio and become what it calls a "comprehensive genomic information company."
The firm reported $3.5 million in revenue for the three months ended Dec. 31, 2016, and $12.9 million for the full year.
CombiMatrix said the move will increase access to the test in the state for women experiencing recurrent pregnancy loss.
The company's testing was successful in more than 90 percent of cases over almost four years, and detected a wide variety of abnormalities.
Ambry's new lab provides a streamlined, automated workflow that has allowed the company to triple its daily testing volume since it opened more than four months ago.
The company reported an 18 percent increase in the number of reproductive health tests completed during the quarter.
Low-coverage, whole-genome sequencing had a diagnostic yield of up to 53 percent in prenatal and postnatal samples referred for chromosomal analyses.
Researchers found that array-based testing and exome sequencing contributed uniquely to ASD diagnosis, and that the diagnostic yield of testing was higher in complex autism cases.
Chromsomal array testing had a higher diagnostic yield in the study than standard procedures, and could have value as a first step before referring patients to further tests.
Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.
The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.
Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.
In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.